Holen Sie sich die Stockscreener-App
84.76
0.69%
0.58
Handel nachbörslich:
84.77
0.010
+0.01%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ALC?
Forum
Prognose
Dividendenhistorie
Schlusskurs vom Vortag:
$84.18
Offen:
$84.18
24-Stunden-Volumen:
910.85K
Relative Volume:
1.16
Marktkapitalisierung:
$41.92B
Einnahmen:
$9.76B
Nettoeinkommen (Verlust:
$1.16B
KGV:
117.72
EPS:
0.72
Netto-Cashflow:
$665.00M
1W Leistung:
+0.70%
1M Leistung:
-0.87%
6M Leistung:
-5.23%
1J Leistung:
+13.41%
1-Tages-Spanne:
$84.06
$85.33
1-Wochen-Bereich:
$83.80
$86.50
52-Wochen-Spanne:
$74.30
$101.10
Alcon Inc Stock (ALC) Company Profile
Vergleichen Sie ALC mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ALC
Alcon Inc
|
84.76 | 41.92B | 9.76B | 1.16B | 665.00M | 2.34 |
|
ISRG
Intuitive Surgical Inc
|
524.43 | 186.79B | 7.87B | 2.24B | 586.00M | 6.22 |
|
BDX
Becton Dickinson Co
|
227.68 | 65.83B | 20.18B | 1.71B | 3.07B | 5.94 |
|
RMD
Resmed Inc
|
237.27 | 34.83B | 4.81B | 1.11B | 1.35B | 7.55 |
|
WST
West Pharmaceutical Services Inc
|
331.40 | 24.00B | 2.88B | 499.60M | 321.60M | 6.74 |
Alcon Inc Stock (ALC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-17 | Bestätigt | Needham | Buy |
| 2024-11-12 | Bestätigt | Needham | Buy |
| 2024-10-10 | Hochstufung | Redburn Atlantic | Sell → Neutral |
| 2024-09-10 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-07-15 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2024-05-15 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2024-04-10 | Eingeleitet | Goldman | Buy |
| 2024-03-14 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2024-02-06 | Fortgesetzt | KeyBanc Capital Markets | Overweight |
| 2024-01-23 | Eingeleitet | Bernstein | Outperform |
| 2023-12-18 | Herabstufung | Redburn Atlantic | Neutral → Sell |
| 2023-12-12 | Eingeleitet | Stifel | Buy |
| 2023-12-04 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2023-08-17 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-05-30 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-05-10 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2023-03-01 | Hochstufung | Societe Generale | Sell → Hold |
| 2022-12-22 | Eingeleitet | Mizuho | Buy |
| 2022-11-17 | Herabstufung | Societe Generale | Hold → Sell |
| 2022-08-11 | Herabstufung | Societe Generale | Buy → Hold |
| 2022-05-13 | Fortgesetzt | Credit Suisse | Outperform |
| 2022-05-12 | Hochstufung | Stephens | Equal-Weight → Overweight |
| 2022-04-08 | Eingeleitet | Needham | Buy |
| 2022-03-11 | Eingeleitet | BofA Securities | Buy |
| 2022-01-18 | Herabstufung | Stephens | Overweight → Equal-Weight |
| 2022-01-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-10-01 | Eingeleitet | Oppenheimer | Perform |
| 2021-07-14 | Eingeleitet | Deutsche Bank | Buy |
| 2021-05-06 | Hochstufung | Citigroup | Sell → Neutral |
| 2021-03-22 | Hochstufung | BTIG Research | Neutral → Buy |
| 2020-11-12 | Herabstufung | Guggenheim | Buy → Neutral |
| 2020-07-06 | Herabstufung | Citigroup | Neutral → Sell |
| 2020-07-06 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2020-06-16 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-04-08 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-03-26 | Hochstufung | Argus | Hold → Buy |
| 2020-03-24 | Hochstufung | Societe Generale | Sell → Hold |
| 2020-03-13 | Hochstufung | UBS | Neutral → Buy |
| 2020-03-05 | Eingeleitet | Citigroup | Neutral |
| 2020-02-26 | Hochstufung | Berenberg | Hold → Buy |
| 2020-01-08 | Eingeleitet | Argus | Hold |
| 2019-10-29 | Eingeleitet | Stephens | Equal-Weight |
| 2019-08-21 | Bestätigt | BofA/Merrill | Neutral |
| 2019-06-24 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2019-06-14 | Eingeleitet | BTIG Research | Neutral |
| 2019-05-10 | Eingeleitet | Robert W. Baird | Outperform |
| 2019-05-02 | Eingeleitet | Credit Suisse | Outperform |
Alle ansehen
Alcon Inc Aktie (ALC) Neueste Nachrichten
Alcon a top pick for 2025 at Needham on upcoming product launches - MSN
Alcon Top Pick for 2025 at Needham, added to Conviction List - MSN
Alcon stock named top pick for 2025 by Needham, positive on margin and earnings growth - Investing.com
Ophthalmic Lasers Market, Competitive Landscape and Market Forecasts to 2030 - GlobeNewswire Inc.
RSI Alert: Alcon (ALC) Now Oversold - Nasdaq
Reasons to Retain Alcon Stock in Your Portfolio for Now - MSN
Does Alcon (VTX:ALC) Have A Healthy Balance Sheet? - Simply Wall St
Alcon Loses Bid To Patent Improved Eye Drug At EPO - Law360
Alcon to lay off dozens of food service workers at Fort Worth campus on Christmas Eve - Yahoo! Voices
Why Alcon (ALC) is a Top Growth Stock for the Long-Term - Yahoo Finance
Alcon Inc. (ALC): A Bull Case Theory - MSN
Fuchs Endothelial Corneal Dystrophy Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | ProQR Therapeutics, Kowa Pharmac, Trefoil Therapeutics, Alcon Inc., Emmecell - Barchart
Photobiomodulation Market Overall Study Report 2024-2031 | - openPR
Dry Eye Disease Market Outlook to 2034: Insights into Epidemiology, Pipeline Developments, and Recent Regulatory Approvals by DelveInsight | Featuring Major Players Like Alcon, Allysta Pharmaceuticals - The Globe and Mail
Ocular Trauma Devices Market Is Booming Worldwide with Alcon, Zeiss, Santen - openPR
India Contact Lenses Market Forecasts and Company Analysis Report 2023-2024 & 2032 Featuring Bausch & Lomb, Alcon Laboratories, J&J, Cooper Vision, Carl Zeiss, Hoya Medical, GKB Ophthalmic and Omni - Yahoo Finance
State Rep. Alcon steps down, cites health concerns - New Mexico Political Report
Jesse Alcon Obituary (2024)Price, UTMitchell Funeral Home, Inc.Price - Legacy.com
Alcon, '3D eye model implementation'Personal vision correction'Personal Eyes' launched in Korea - SportsChosun
What Analyst Projections for Key Metrics Reveal About Alcon (ALC) Q3 Earnings - MSN
Alcon cuts 2024 forecasts, as slow US hits surgical unit - MSN
Alcon Q3 Earnings Top Estimates, Margins Up, Stock Gains in Afterhours - MSN
Impressive Earnings May Not Tell The Whole Story For Alcon (VTX:ALC) - Yahoo Finance
Lights, Camera, Lawsuit: Musk and Tesla in Hot Water Over Claimed “Blade Runner” Rip-Off - JD Supra
Alcon (ALC) is a Top-Ranked Value Stock: Should You Buy? - Yahoo Finance
Most Venture Investors Want Their Startups to Go Public. Not This One. - The Wall Street Journal
Alcon Laboratories is considering a major $100M expansion of its Fort Worth campus - AOL
Results: Alcon Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts - Yahoo Finance
Reiterate Overweight on Alcon with $107 target post 3Q results - Investing.com
Alcon Inc. (NYSE:ALC) Q3 2024 Earnings Call Transcript - Insider Monkey
Alcon shares maintain Buy rating and $107 target post-results By Investing.com - Investing.com Australia
Earnings call: Alcon reports solid Q3 growth, updates full-year guidance - Investing.com UK
Alcon: Q3, Slight Guidance Cut Is Not Something Structural - Seeking Alpha
Alcon Third Quarter 2024 Earnings: EPS Beats Expectations - Yahoo Finance
3 Focus Stocks: Alcon, Up Fintech, and Monolithic Power Systems - Baystreet.ca
ALCON : Q3 miss and an outlook downgrade should not be seen as worrisome - Marketscreener.com
Pharmaceuticals: Alcon records lower growth in the third quarter | blue News - bluewin E-Mail
Alcon Lowers Financial Outlook After US Sales Slump - Finimize
Alcon trims revenue forecast - 69News WFMZ-TV
Alcon shares maintain Buy rating and $107 target post-results - Investing.com
Alcon Reports Solid Third-Quarter 2024 Results, including Double-Digit Earnings Growth and Record Cash Generation - sharewise
Alcon Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Alcon (ALC) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
Alcon falls 6% as company trims 2024 sales outlook - MSN
Alcon Posts Higher 3Q Sales and Profit, Lowers 2024 Sales View - MarketWatch
Alcon’s Strong Q3 2024 Results Boost Investor Confidence - TipRanks
Cell therapy startup's IPO plans thrown in limbo amid legal spat with investor Alcon - Endpoints News
Finanzdaten der Alcon Inc-Aktie (ALC)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.46%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):